Crinetics Pharmaceuticals Inc Stock News

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript

Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, de

SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, Febru

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2024, the Compensation Committee of Crinetics' Board of Directors grant

Today, we take a deeper look at Crinetics Pharmaceuticals, Inc., which has seen a significant increase in its stock price in recent months. The company's primary drug candidate, paltusotine, looks lik

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI He

Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing turbulence rig

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at th

Crinetics Pharmaceuticals' lead candidate could be commercialized soon. It'll have a hard time gaining market share quickly if it gets approved for sale.

Crinetics Pharmaceuticals announced positive late-stage trial data for its acromegaly drug this week. If approved, analysts think this oral therapy could rake in nearly half a billion in annual sales

Crinetics focuses on treatments for rare endocrine-related diseases and cancers. The company had only $264.5 million in cash as of the second quarter.

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock is surging today, last seen up 72.7% to trade at $27.58 at last check, after the late stage trial for its experimental drug paltusotine to treat a r